September 2010 Volume 6, Issue 9

Volume 6, Issue 9 | September 2010

September 2010

In this Issue

Research & Development

Drug Discovery News Placeholder Image

The French connection

Seeking to acquire Genzyme, sanofi-aventis goes public with a nearly $20 billion cash offer
Drug Discovery News Placeholder Image

Jumping into the game

Envoy to seek new Parkinson’s disease therapy with Scripps Research Institute
Drug Discovery News Placeholder Image

Signaling the pathway to antibody development

NovImmune enters into exclusive antibody licensing agreement with Genentech
Drug Discovery News Placeholder Image

Striking a nerve

Gladstone, Danish drugmaker Lundbeck sign neurological disease research agreement
Drug Discovery News Placeholder Image

7,000 points of light

Sigma Life Science and Boston University awarded NHLBI grant to probe samples from Framingham Heart Study for biomarkers in cardiovascular disease

Global News

Drug Discovery News Placeholder Image

Shire hungry for share of gastro market

British drugmaker announces plans to buy Movetis NV
Drug Discovery News Placeholder Image

A sure selection

Agilent Technologies and Wellcome Trust Sanger Institute develop all-exon target enrichment tool for next-generation sequencing
Drug Discovery News Placeholder Image

Easing the pain

BioFocus and University of Bristol enter drug discovery collaboration in diabetes-related chronic neuropathic pain
Drug Discovery News Placeholder Image

A dowry to the seal the engagement

Actelion obtains option to acquire privately held Trophos for just under $13 million
Drug Discovery News Placeholder Image

Tour of Italy

Aptuit, Siena Biotech forge strategic partnership for former GSK facility in Verona

Instruments & Informatics

Drug Discovery News Placeholder Image

Illumina shines light on Helixis acquisition

Company announces purchase, launch of new PCR product in Q2 financial report
Drug Discovery News Placeholder Image

A VisEn-ary acquisition

PerkinElmer’s acquisition of VisEn Medical will add in vivo molecular imaging capabilities to enhance preclinical research
Drug Discovery News Placeholder Image

A collaboration in the Cleve

EMD Millipore and Cleveland Clinic collaborate on method to rapidly stain and assess tissue
Drug Discovery News Placeholder Image

Automation solution enables protein purification

PhyNexus, Tecan collaborating on development of standard processes
Drug Discovery News Placeholder Image

Axela’s acquisition of Xceed Molecular hits snag

Plan to create a powerhouse in robust and easy-to-use systems for translational medicine put on hold as recession hits Canadian life sciences companies hard

Special Reports

Drug Discovery News Placeholder Image

Pharmacogenomics harnesses power of prediction, personalization

Branch of pharmacology stands at the precipice of the era of personalized medicine in cancer treatment
Drug Discovery News Placeholder Image

Getting down to basics

Researchers dig deep into the genome, not just to establish the causes of cancer, but also the best approaches to treatment

Editor's Focus

Drug Discovery News Placeholder Image

When shareholders attack, it’s not just the news that suffers

It’s the phone call or e-mail that every publication editor dreads. It comes seconds before deadline time, as the content your editorial team has worked for the last month to produce is committed to print. It comes from a writer whose story has morphed so materially from its original state that it can’t run as planned—usually leaving a black hole in your layout to be filled at the eleventh hour.

Commentary

Drug Discovery News Placeholder Image

Guest Commentary: Prioritizing hits based on drug-target residence time

Amid the complexity and expense of the small-molecule drug discovery process, from identification and validation of a “drugable” target to the development of an understanding of the impact of pharmacogenomic differences in patient populations on drug action, lies the “hit-to-lead” process in which compounds that show activity in an assay system are iteratively improved upon through medicinal chemistry that is guided by more detailed assays and filtering criteria.

Patent News

Drug Discovery News Placeholder Image

Lilly loses method patent after use was disclosed in earlier patent

Eli Lilly & Co. recently lost an appeal from a final judgment of the U.S. District Court for the Eastern District of Michigan, finding claims 2, 6, and 7 of U.S. Patent No. 5,464,826 invalid for obviousness-type double patenting over its earlier U.S. Patent No. 4,808,614. (See, Sun Pharmaceutical Industries v. Lilly, U.S. Court of Appeals for the Federal Circuit, 2010-1105).

Diagnostics

Drug Discovery News Placeholder Image

Korea collaboration is key for cancer research

Pfizer forms research partnership with South Korea’s Samsung to analyze, treat liver cancer tumors
Drug Discovery News Placeholder Image

Cancer double-team

Novartis, Pathwork Diagnostics forge collaboration to develop and sell diagnostics
Drug Discovery News Placeholder Image

IRIS takes AlliedPath to personalized medicine

Company closes on acquisition, gains laboratory offering MDx services
Drug Discovery News Placeholder Image

Penning a pair of diagnostic deals

Eurogentec enters into two agreements with BD Diagnostics regarding molecular diagnostics: one in technology transfer and the other in suppl

Government Watch

Drug Discovery News Placeholder Image

The big decision on Bilski

Supreme Court patent ruling on Bilski means much for diagnostics, less for pharma
Drug Discovery News Placeholder Image

DTC genetic testing faces federal fire

GAO investigators say DNA tests give bogus results, mislead consumers; FDA launches probe of several companies
Drug Discovery News Placeholder Image

Is close enough good enough for medicine?

Proposal to allow biosimilars takes heat at Congressional caucus hearing
Drug Discovery News Placeholder Image

2010 U.S. healthcare bill: Good, bad or double-edged sword?

Report examines reform’s impact on pharma

Omics & Systems Biology

Drug Discovery News Placeholder Image

Partnership is primed and ready

FivePrime Therapeutics partners with GSK on skeletal muscle disorders
Drug Discovery News Placeholder Image

AB SCIEX and ETH Zurich Institute join forces to advance systems biology

Collaboration to create new methods on AB SCIEX QTRAP 5500 System for faster and broader quantitative analysis in support of metabolomics studies
Drug Discovery News Placeholder Image

A new avenue for Alzheimer’s

MIT researchers say SIRT1, a gene implicated in aging, may control production of protein fragments that make up amyloid plaques
Drug Discovery News Placeholder Image

Nitto Denko and Quark Pharmaceuticals to jointly develop siRNA anti-fibrotic drug

Quark also signs licensing option agreement with Novartis for p53 suppressor
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue